Treatment of Parkinson's Disease With Lergotrile Mesylate

Abraham Lieberman, Eli Estey, Mark Kupersmith, Govindan Gopinathan, Menek Goldstein

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Lergotrile mesylate, an ergot alkaloid derivative and putative dopamine agonist, was effective in the majority of patients with Parkinson's disease who were showing signs of disease progression despite treatment with levodopa combined with a peripheral decarboxylase inhibitor (carbidopa). Among 20 patients completing a six-month trial, there was a significant (P<.01) reduction in rigidity, tremor, bradykinesia, gait disturbance, and total score when lergotrile was added to levodopa plus carbidopa. Mean daily dose of lergotrile mesylate was 52 mg, and the mean daily dose of levodopa was reduced by 15%. Abnormal involuntary movements were decreased on addition of lergotrile and reduction in levodopa while mental changes and orthostatic hypotension were increased. Elevations in serum transaminase levels were noted in three patients. The ergot alkaloids promise to be an important new class of antiparkinsonian drugs.

Original languageEnglish
Pages (from-to)2380-2382
Number of pages3
JournalJAMA - Journal of the American Medical Association
Volume238
Issue number22
DOIs
StatePublished - 28 Nov 1977
Externally publishedYes

Fingerprint

Dive into the research topics of 'Treatment of Parkinson's Disease With Lergotrile Mesylate'. Together they form a unique fingerprint.

Cite this